Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease that affects red blood cells, causing symptoms like dark urine, ...

Our easy-to-read patient fact sheet compares and contrasts sinus arrhythmia vs AFib (atrial fibrillation) symptoms.

Health Canada has approved Novartis Canada’s Fabhalta (iptacopan capsules) as the first oral monotherapy to treat adults with paroxysmal nocturnal haemoglobinuria (PNH) and haemolytic anaemia.

At this construction site, this front loader has a bit of trouble controlling its extremely long pole. When the front loader ...

Living with BPPV means navigating a world where severe dizziness can strike without warning, disrupting everyday life. Senior ...

Turkish Airlines has posted a robust 2024 financial performance, lifted by soaring cargo revenue and capacity and network ...

Canada NewsWire MONTREAL, Feb. 13, 2025 MONTREAL, Feb. 13, 2025 /CNW/ - Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance for Fabhalta® ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

Health Canada has approved Novartis Canada’s Fabhalta (iptacopan capsules) as the first oral monotherapy to treat adults with paroxysmal nocturnal haemoglobinuria (PNH) and haemolytic anaemia.

Omeros Corporation's stock surges as narsoplimab data shows 68% lower death risk in HSCT-TMA patients. Click to learn about the potential and risks of OMER stock.